59 completed, 8 unknown, 7 recruiting, 6 active not recruiting. 29 Phase 1, 20 Phase 3, 16 Phase 2, 14 Phase 4, 3 Not applicable.
Follow Rilpivirine: new trials by email Literature Review of Rilpivirine trials Research Report on Rilpivirine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy Every 4-week long-acting injectable cabotegravir and rilpivirine - HIV -1 Infection | Not yet recruiting | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | 40 | 2026-10-15 | 2026-08-27 | |
| Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy Lenacapavir, Lenacapavir Tablet, Teropavimab - HIV Infections | Phase 3 | Recruiting | Gilead Sciences | 590 | 2026-07-14 | 2026-08-14 |
| Targeted Therapies for Immunological Non-Responders in People With HIV: A Multicenter Clinical Study cART + Rilpivirine, cART - Immunological Non-Responders in People With HIV | Phase 2 | Recruiting | Beijing 302 Hospital | 21 | 2026-06-15 | 2026-09-24 |
| PERsistance of Long-Acting inJEctable CAB+RPV in a Cohort of Virologically-suppressed PLWH: a Real-life Study Cabotegravir/Rilpivirine - HIV-1-infection | Not yet recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 200 | 2026-06-01 | 2026-05-12 | |
| Optimization of Antiretroviral Therapy in Patients With AIDS-Related Lymphoma Oral Antiretroviral Therapy, albuvirtide, Cabotegravir/Rilpivirine - AIDS-related Lymphoma, HIV Infection | Not applicable | Recruiting | Shanghai Public Health Clinical Center | 60 | 2026-05-26 | 2026-07-27 |
| Long-Acting Cabotegravir and Rilpivirine in People Living With HIV-1 Subtype A6: A Real-World Retrospective Study Cabotegravir Plus Rilpivirine Long-Acting Injectable - Human Immunodeficiency Virus (HIV)-1 Infection, HIV-1 Subtype A6 Infection | Recruiting | Pomeranian Medical University Szczecin | 250 | 2026-05-12 | 2026-06-11 | |
| Research on the Psychological Status of Patients With HIV-1 Infection All kinds of INSTI medications, All kinds of conventional medications - HIV-1-infection, Anxiety Depression | Not yet recruiting | Shanxi Bethune Hospital | 500 | 2025-08-01 | 2025-07-23 | |
| Long-acting Injectable Antiretroviral Treatment to Improve HIV Treatment Among Justice-involved Persons Being Released to the Community The first FDA-approved LAI ART regimen includes an integrase inhibitor, cabotegravir (CAB), and a non-nucleoside reverse transcriptase inhibitor, rilpivirine (RPV) combined 4 wks - HIV | Not yet recruiting | The Miriam Hospital | 20 | 2025-02-01 | 2025-01-15 | |
| Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs Collaborative drug therapy management model, Cabotegravir/Rilpivirine - Hiv | Phase 2 | Active not recruiting | Yale University | 50 | 2024-08-01 | 2026-10-13 |
| Outcomes of the PLHIV With Suboptimal Viral Suppression to Injectable Long-acting Antiretrovirals cabotegravir/rilpivirine (600mg/ 900mg), Antiretroviral Combinations - HIV-1-infection, Non-Adherence, Medication | Phase 3 | Recruiting | Chang Gung Memorial Hospital | 40 | 2024-07-19 | 2024-08-23 |
| Clinical Effectiveness-Implementation Hybrid Type 2 Study on Home-Delivered Cabenuva for People Living With HIV Who Are Not Retained in Care rilpivirine/cabotegravir - HIV | Unknown | Whitman-Walker Institute | 180 | 2023-11-01 | 2024-04-25 | |
| Implementation of Out-of-HOspital Administration of the Long-Acting Cabotegravir+Rilpivirine Hospital long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg administration, Out of Hospital long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg administration - HIV-1 Infection | Phase 4 | Completed | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | 103 | 2023-09-26 | 2025-07-14 |
| A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy DTG/3TC, Cabotegravir (CAB) LA, Rilpivirine (RPV) LA - HIV Infections | Phase 3 | Completed | ViiV Healthcare | 171 | 2023-07-06 | 2026-05-27 |
| A Real-life Study of the Use of Cabotegravir Plus Rilpivirine Long-acting in ART-experienced Pre-treated People With HIV Cabotegravir Injectable Product, Rilpivirine Injectable Product - Human Immunodeficiency Virus | Active not recruiting | University Hospital Virgen de las Nieves | 287 | 2023-06-01 | 2024-07-24 | |
| Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day, Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day, Continue with their previous treatment. Any previous HAART that does not contain Rilpivirine. - HIV Infections, Fatty Liver Disease | Phase 4 | Completed | Fundacion SEIMC-GESIDA | 63 | 2023-05-26 | 2025-07-18 |
| Improving HIV-1 Control in Africa With Long Acting Antiretrovirals Cabotegravir/Rilpivirine, Antiretroviral - HIV-1-infection | Phase 3 | Completed | MRC/UVRI and LSHTM Uganda Research Unit | 540 | 2022-12-08 | 2026-10-09 |
| Cohort Study of HIV-positive People, Treated With Long Acting Antiretroviral Therapy Cabotegravir 600mg/3mL, Rilpivirine 900mg/3mL - HIV Infections | Recruiting | Castagna Antonella | 1500 | 2022-07-17 | 2026-10-19 | |
| Combined Injectable Treatment for HIV and OUD Combined LAI Treatment: Cabenuva and Sublocade - Human Immunodeficiency Virus, Opioid Use Disorder | Phase 2 | Withdrawn | Rhode Island Hospital | 2022-04-01 | 2026-02-18 | |
| Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures VOCABRIA 30Mg Tablet, EDURANT 25Mg Tablet, Cabotegravir Injectable Suspension - HIV Infections | Unknown | University of Zurich | 600 | 2022-03-01 | 2024-05-08 | |
| A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Rilpivirine Tablets (RPV) Azvudine tablets(FNC) and Rilpivirine Tablets (RPV), Azvudine tablets (FNC) and Rilpivirine Tablets (RPV) - Healthy | Phase 1 | Completed | Henan Genuine Biotech Co., Ltd. | 15 | 2022-02-21 | 2025-06-03 |
Showing 20 of 91. Sign in to see all of them.
HIV Infections (32) · Acquired Immunodeficiency Syndrome (23) · Infections (4) · Hepatitis C (3) · Body Weight Changes (1) · Cardiovascular Abnormalities (1) · Cardiovascular Diseases (1) · Cognition Disorders (1) · Communicable Diseases (1) · HIV Seropositivity (1) · HIV-Associated Lipodystrophy Syndrome (1) · Hepatitis (1) · Hepatitis C, Chronic (1) · Inflammation (1) · Lymphoma, AIDS-Related (1)
Tibotec Pharmaceuticals, Ireland (14) · ViiV Healthcare (10) · Janssen Research & Development, LLC (5) · Janssen R&D Ireland (4) · National Institute of Allergy and Infectious Diseases (NIAID) (4) · Janssen Sciences Ireland UC (3) · St Stephens Aids Trust (3) · Janssen Pharmaceutical K.K. (2) · Mahidol University (2) · Makerere University (2) · A.O. Ospedale Papa Giovanni XXIII (1) · ANRS, Emerging Infectious Diseases (1) · Andrew Carr (1) · Aptorum International Limited (1) · Assistance Publique - Hôpitaux de Paris (1)
United States (33) · South Africa (15) · Spain (15) · France (12) · Thailand (12) · Canada (10) · United Kingdom (10) · Germany (9) · Uganda (9) · Australia (8) · Belgium (8) · Italy (8) · Puerto Rico (8) · Argentina (7) · Russia (7)
Mohammed Lamorde, PhD (2) · Aadia Rana, M.D. (1) · Aditya H. Gaur, MD (1) · Akil Jackson, Dr (1) · Alan Winston, Dr (1) · Alan Winston, MBChB MD (1) · Andrew Zolopa, MD (1) · Ann Melvin, MD, MPH (1)
PMID 35508986, PMID 37452174, PMID 39052748, PMID 40655875, PMID 22532465, PMID 23714781, PMID 33136751, PMID 34648734, PMID 37776478, PMID 16470119, PMID 16988514, PMID 18366444, PMID 18795962, PMID 18989231, PMID 19926964, PMID 20002783, PMID 20632458, PMID 21283017, PMID 21763935, PMID 21763936, PMID 22083071, PMID 22129166, PMID 23305215, PMID 23392467, PMID 23824675, PMID 23979733, PMID 24161160, PMID 24203510, PMID 25162818, PMID 25261418, PMID 25407158, PMID 25950206, PMID 25959631, PMID 25975423, PMID 25988676, PMID 26123937, PMID 26169561, PMID 26201299, PMID 26202768, PMID 26918544, PMID 27540363, PMID 27658864, PMID 28750935, PMID 28994660, PMID 29186458, PMID 29335895, PMID 29369162, PMID 29520730, PMID 29528944, PMID 30134297
2014 (3), 2015 (2), 2016 (2), 2008 (1), 2017 (1), 2018 (1), 2023 (1), 2025 (1), R01AI155052 (1), R34DA057165 (1), UM1AI068616 (1), UM1AI068619 (1), UM1AI068632 (1), UM1AI106716 (1)